Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Investor Presentation (December 2025)
42 slides from Eris Lifesciences's investor presentation, Dec 3, 2025
Slide 1: Exchange filing cover letter: Corporate Presentation
Date: 03 December 2025 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai – 400001 Bandra (E) Mumbai – 400051 Security Code: 540596 Symbol: ERIS SUBJECT: CORPORATE PRESENTATION REF: REGULATION 30 OF SEBI (LODR)
Slide 2: Corporate Presentation December 2025
CORPORATE PRESENTATION December 2025
Slide 3: Introduction, Domestic Branded Formulations, Technology & Manufacturing, International Business
• Introduction • Domestic Branded Formulations • Technology & Manufacturing • International Business 2
Slide 4: Introduction to Eris
INTRODUCTION TO ERIS ▪ Domestic Branded Formulations ▪ Among the Top-20 Indian pharmacos in less than 20 years since inception; youngest company on the list ▪ Strong presence in Super-Specialty segment accounting for 80% of revenue ▪ Top-5 market position (by revenue) in Anti-Diabetes therapy with a
Slide 5: Leveraged acquisitions to enter dermatology, injectables & biologics
LEVERAGED ACQUISITIONS TO ENTER DERMATOLOGY, INJECTABLES & BIOLOGICS…. FY22 Revenue INR 195 cr; FY23 Revenue INR 280 cr; 10% EBIDTA margin Revenue INR 50 cr 37% EBIDTA margin Oaknet – entry Derma Brands from Swiss Parenterals Eris BioNxt into Derma (INR Reddy’s (INR 275 cr.) Ltd. (INR 875 cr.) (INR
Slide 6: Significant expansion in therapeutic & geographic footprints
…WITH A SIGNIFICANT EXPANSION IN THERAPEUTIC & GEOGRAPHIC FOOTPRINTS Geographies We now have manufacturing ops across 6 1 Expanded geographic reach from India to globally accredited/ compliant facilities USA Africa, Asia-Pacific, Latam and the deploying a diverse suite of technologies CIS/Middle Eas
Slide 7: All acquisitions integrated; margins expanded 400 bps since FY23
ALL ACQUISITIONS INTEGRATED; MARGINS EXPANDED 400 BPS SINCE FY23 REVENUE (INR CR) EBITDA (INR CR) PAT (INR CR) 1,200 36% 36% 37% 35% 36% 1,000 406 397 2,894 35% 374 375 800 34% 34% 2,009 260 1,685 1,565 600 32% 33% 1,347 32% 400 31% 200 30% 485 537 675 1,017 565 0 29% FY22 FY23 FY24 FY25 H1FY26 FY22
Slide 8: Entered an era of accelerated EPS growth over FY26-FY28
ENTERED AN ERA OF ACCELERATED EPS GROWTH OVER FY26-FY28 Last 4 years’ Investment Cycle Outlook – FY26 and Beyond FY 22 FY 25 A • Inflection point in EPS growth starting FY26, Assets* 921 ~5,400 6x driven by multiple factors • Growth and margin improvement in EPS 29.9 ~28 19% acquired businesses • De
Slide 9: Strategic investments in diabesity & injectables over next 3 quarters
STRATEGIC INVESTMENTS IN DIABESITY & INJECTABLES OVER NEXT 3 QUARTERS Market Opportunity Strategic investment • Capex outlay of Rs. 380-400 cr. over the RoW market opportunity Insulin capacity doubling 1 next 3 quarters in Insulins/ GLP-1 at Bhopal – Rs. 150 cr. • Will be funded through internal Ram
Slide 10: Net-debt-to-EBITDA ratio of <1.5x by Dec 2026
WE EXPECT TO ACHIEVE A NET-DEBT-TO-EBIDTA RATIO OF < 1.5x BY DEC 2026 Debt-to-EBIDTA Ratio Debt-to-EBIDTA Ratio Debt Reduction guidance Plan shared at the start of FY26 Outlook at the end of Q2-FY26 • Net Debt to TTM EBIDTA ratio has significantly Outstanding Debt to Outstanding Debt to As On Date r
Slide 11: Domestic Branded Formulations section
• Introduction • Domestic Branded Formulations • Technology & Manufacturing • International Business 10
Slide 12: Expanded domestic CVM/TAM by 72% during Apr-23 to Oct-2025
EXPANDED OUR DOMESTIC CVM/ TAM BY 72% DURING APR-23 TO OCT-2025 MAT Mar’22 Revenue = Rs. 1,662 cr. MAT Oct’25 Revenue = Rs. 2,970 cr. Rest Rest WHC Gastro Critical Care Oral Anti- 8% Oral anti Nephro diabetes 3% 4% CNS 4% diabetes 3% CNS 4% 23% 8% 32% 4% WHC 5% VMN 20% 12% 14% Insulins + GLP-1 VMN 1
Slide 13: Dominant power brands; leveraged LOE opportunities
DOMINANT POWER BRANDS; SUCCESSFULLY LEVERAGED LOE OPPORTUNITIES Our Top 20 Mother Brands with Market Shares Successfully Leveraged LOE (Loss of Exclusivity) Opportunities MAT Oct’25 Sales (₹ Cr) Market share 333 286 2,989 4% Vildagliptin – Launched Dec-19 168 170 1,713 9% Rank #1 among BGx 163 158 1
Slide 14: Established player in anti-diabetes with full-spectrum presence
ESTABLISHED PLAYER IN ANTI-DIABETES WITH A FULL-SPECTRUM PRESENCE Eris ranks in Anti-Diabetes therapy Eris market share in Anti-Diabetes* By Revenue* By # Rx** 6.1% 5 6 4.9% Mar'23 Oct'25 • The only 18-year old company to have achieved a Top-5 market rank in Anti-Diabetes • And the only company with
Slide 15: Significant expansion in insulins market share post Biocon acquisition
SIGNIFICANT EXPANSION IN INSULINS MARKET SHARE POST BIOCON ACQUISITION Growth in Eris market share in Insulins (RHI + Glargine) 100% = Rs. 2,400 cr. Rs. 2,474 cr. • Acquisition of Biocon India Rest 4% 4% Branded Business in Apr 2024 Wockhardt 4% 4% ERIS 10% 15% • Post-merger integration and Lupin 16
Slide 16: Eris-Biocon partnership in insulins being significantly expanded
THE ERIS-BIOCON PARTNERSHIP IN INSULINS IS BEING SIGNIFICANTLY EXPANDED Threefold expansion in Insulin partnership Insulin Supply Chain post deal 1. We are adding Aspart to the scope of the Biocon to manufacture and supply the Drug strategic collaboration between Eris and Substance for RHI, Glargine
Slide 17: India RHI, Glargine and Aspart – well positioned for success
INDIA RHI, GLARGINE AND ASPART – WE ARE WELL POSITIONED FOR SUCCESS Size of the market opportunity Product/ Market Market Size Competitive situation Rs. 3,700+ cr. market, Human Insulin (RHI) Vials Rs. 1,000 cr. p.a. 65% Innovator; 35% Gx traditionally Human Insulin (RHI) Carts Rs. 750+ cr. p.a. 60%
Slide 18: GLP-1 continues to be an exciting market opportunity
GLP-1 CONTINUES TO BE AN EXCITING MARKET OPPORTUNITY FOR US ▪ Our early hypothesis of a large and fast-emerging GLP-1 market in India stands validated by the latest AWACS data Our “Right to Win” ▪ As expected, Endocrinologists/ Diabetologists are leading the prescriptions with a 66% share We will le
Slide 19: India-centric studies focused on improving disease management
INDIA-CENTRIC STUDIES FOCUSED ON IMPROVING DISEASE MANAGEMENT India Head and Neck Cancer Study About the Study About the Study About the Study Long Term Results Of A Randomized Cardiovascular risk in newly diagnosed One of its kind study on Hypertension Phase III Study Of Nimotuzumab T2DM patients i
Slide 20: Patient Care Initiative – a differentiated service platform
PATIENT CARE INITIATIVE – A DIFFERENTIATED SERVICE PLATFORM Key elements of Eris Patient Care Platform ▪ Objective - Bring cutting- edge healthcare solutions to patients through the involvement of Key Opinion Leaders ▪ State-of-the-art diagnosis at home, followed by customised treatment plans ▪ Help
Slide 21: Technology & Manufacturing section
• Introduction • Domestic Branded Formulations • Technology & Manufacturing • International Business 20
Slide 22: State-of-the-art R&D centre with wide range of dosage capabilities
STATE-OF-THE-ART R&D CENTRE WITH A WIDE RANGE OF DOSAGE CAPABILITIES R&D Facility is situated in our Unit-3 Campus, which is a 15- Formulation Development Capabilities minute commute from our sterile facilities (Unit-1 and Unit-2) Dedicated Production Lines for various dosage forms: ✓ State-of-the-a
Slide 23: Diabesity product pipeline spanning insulin analogs and GLP-1
OUR DIABESITY PRODUCT PIPELINE SPANNING INSULIN ANALOGS AND GLP-1 Candidate H1-F26 H2-F26 H1-F27 H2-F27 H1-F28 H2-F28 Insulin Analogues ~ Rs. 1,700+ cr. p.a. market with 3-year CAGR of 11% - presently dominated by Innovator Aspart Aspart Mix Form. Dev. Ph-I trial Phase-III trial Degludec Preclinical
Slide 24: Building momentum in small molecule pipeline of innovative FDCs
BUILDING MOMENTUM IN OUR SMALL MOLECULE PIPELINE OF INNOVATIVE FDCs* FY23 FY24 FY25 FY26 Start of Year 3 7 14 0 pipeline Additions 5 8 10 17 during the year Launches 2 4 3 11 (Planned) in the year Pipeline entering 7 14 20 (for FY27) 3 next year A modest beginning in FY23……now a pipeline of 30+ acti
Slide 25: Six manufacturing units across a wide range of tech/dosage forms
SIX MANUFACTURING UNITS ACROSS A WIDE RANGE OF TECH/ DOSAGE FORMS AMD CAMPUS – INJECTABLES, AMD – GENERAL INJECTABLES AMD – BETALACTAM INJECTABLES DERMATOLOGY AND ORAL SOLIDS BIOLOGICS FILL-FINISH - BHOPAL BIOLOGICS BULK - CHENNAI GUWAHATI – ORAL SOLIDS 24
Slide 26: EU-GMP and ANVISA approved sterile manufacturing facilities
EU-GMP AND ANVISA APPROVED STERILE MANUFACTURING FACILITIES Unit 1 – General Injectables – Ampoules, Vials, Dry Powders, PFS, Lyophilised Dosage Form Units per month Liquid Ampoules 8 million Liquid Vials 3.6 million Dry Powder Vials 2.6 million Prefilled Syringes 1.3 million Lyophilized Vials 800,0
Slide 27: Our Bhopal biologics manufacturing facility
OUR BHOPAL BIOLOGICS MANUFACTURING FACILITY Capabilities across 4 presentations ✓ Liquid Vials ✓ Prefilled Syringes ✓ Lyophilised Vials ✓ Liquid Cartridges • Presently manufacturing Liquid and Lyophilised vials for Insulin Glargine and RHI (Recombinant Human Insulin) • Will commission cartridge manu
Slide 28: International Business section
• Introduction • Domestic Branded Formulations • Technology & Manufacturing • International Business 27
Slide 29: International business – presence across 70+ world markets
INTERNATIONAL BUSINESS – PRESENCE ACROSS 70+ WORLD MARKETS Emerging • Our International presence Middle East Presence spans 70+ in the EU countries across Latin America, Pan-Africa Africa, Asia Pacific, the Middle East and CIS countries Central & Latin APac • ANVISA approval for America injectable f
Slide 30: Leveraging manufacturing footprint to expand global access
LEVERAGING OUR MANUFACTURING FOOTPRINT TO EXPAND OUR GLOBAL ACCESS Approved India PIC/s Anvisa EU Approvable FY23 Eris AMD * Evolving from an “India-only” business to an FY24 Swiss “India + International” FY25 Eris Bhopal business FY25 Levim * Approved by Brazil (Anvisa) in Aug 2025 (oral liquid lin
Slide 31: Key international accreditations for our injectable facilities
KEY INTERNATIONAL ACCREDITATIONS FOR OUR INJECTABLE FACILITIES 30
Slide 32: Why did we find Swiss Parenterals attractive?
REMINDING OURSELVES – WHY DID WE FIND SWISS PARENTERALS ATTRACTIVE? Value Driver Key attributes Our thesis in Exports Pure-play injectables 60% General and 40% • We found Swiss to be the business Betalactams only RoW focused Indian pharmaco with 60%+ ROCE with a strong reputation for Marquee regulat
Slide 33: We undertook focused action to expand our capabilities
WE WEUNDERTOOK UNDERTOOKFOCUSED FOCUSEDACTION ACTIONTO TOEXPAND EXPANDOUR OURCAPABILITIES CAPABILITIES 1 2 3 R&D/ Tech. Transfer Capability Manufacturing & Quality Go-to-Market Capability • Onboarded a new Head-R&D • Secured our first Brazilian • Strengthened our customer- from a Top-10 Indian Pharm
Slide 34: Significant momentum and revenue visibility from these actions
SIGNIFICANT MOMENTUM AND REVENUE VISIBILITY FROM THESE ACTIONS We are happy to share that we received our first Purchase Order from a European client on an Injectable CDMO project • Swiss to exclusively manufacture for the Reference Listed Drug (RLD) – i.e., the innovator brand of the product • Firs
Slide 35: Swiss Parenterals – summary of business transformation
SWISS PARENTERALS – SUMMARY OF BUSINESS TRANSFORMATION Driving significant improvement in Stickiness of Business • Initiated Unit-3 Expansion in FY24 FY27P expansion at a Capex EU-CDMO book of Rs. 130 cr. of business* Percentage of from revenue from Sub 2% ~ 30% • Will be an EU and Regulated Markets
Slide 36: Safe Harbour Statement
SAFE HARBOUR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 37: Eris Lifesciences Ltd.
Eris Lifesciences Ltd. CORPORATE OFFICE: Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat 380054 CIN: L24232GJ2007PLC049867 Website : www.eris.co.in IR Contact Kruti Raval kruti@erislifesciences.com 36
Slide 38: Appendix
a = V4 “2 — APPENDIX
Slide 39: Business structure and holdings
BUSINESS STRUCTURE AND HOLDINGS Eris Lifesciences Limited Eris Therapeutics Limited Promoters 9% 1% Eris Oaknet Healthcare Private Ltd (Step-down subsidiary) Aprica Healthcare Limited (Step-down subsidiary) DIIs 16% Eris Healthcare Private Limited FPIs 55% Eris M. J. Biopharm Private Limited Public
Slide 40: Financial Summary (1/2)
FINANCIAL SUMMARY (1/2) P&L Summary FY19 FY20 FY21 FY22 FY23 FY24 FY25 Revenue 982 1,074 1,212 1,347 1,685 2,009 2,894 Gross Profit 828 903 974 1,089 1,333 1,629 2,180 Gross Profit Margin (%) 84.4% 84.0% 80.3% 80.8% 79.1% 81.1% 75.3% Operating EBITDA 345 368 431 485 537 675 1,017 Operating EBITDA Ma
Slide 41: Financial Summary (2/2)
FINANCIAL SUMMARY (2/2) FY19 FY20 FY21 FY22 FY23 FY24 FY25 BS Summary Mar'19 Mar'20 Mar'21 Mar’22 Mar’23 Mar’24 Mar’25 Margin (%) Share Capital 14 14 14 14 14 14 14 Gross Margin 84.4% 84.0% 80.3% 80.8% 79.1% 81.1% 75.3% Reserves 1,137 1,283 1,563 1,895 2,182 2,573 2,841 EBITDA Margin 35.1% 34.3% 35.
Slide 42: Thank You
THANK YOU Eris Lifesciences 41
Eris Lifesciences — Investor Presentation (December 2025) on 6ix